<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>OBJECTIVE: To investigate the role of the burden of abnormal hematopoietic clone in the development of <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) </plain></SENT>
<SENT sid="1" pm="."><plain>METHODS: The ratio of the bone marrow cells with abnormal chromosomes to the total counted bone marrow cells was regarded as the index of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone burden </plain></SENT>
<SENT sid="2" pm="."><plain>The disease severity related parameters including white blood cell count, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, platelet count, <z:chebi fb="4" ids="24996">lactate</z:chebi> dehydrogenase level, bone marrow blast, myeloid differentiation index, micromegakaryocyte, transfusion, interleukin-2, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:mp ids='MP_0001651'>necrosis</z:mp> factor (TNF), CD4+ and CD8+ T cells of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients were assayed, and the correlations between those parameters and <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone burden were also analyzed </plain></SENT>
<SENT sid="3" pm="."><plain>RESULTS: The clone burden of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients was 67.4% +/- 36.2% </plain></SENT>
<SENT sid="4" pm="."><plain><z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> clone burden positively correlated with bone marrow blasts (r = 0.483, P &lt; 0.05), negatively with <z:chebi fb="0" ids="35143">hemoglobin</z:chebi> level (r = -0.445, P &lt; 0.05) </plain></SENT>
<SENT sid="5" pm="."><plain>The number of blasts, <z:chebi fb="0" ids="35143">hemoglobin</z:chebi>, and erythrocytes in high clone burden (&gt; 50%) and low clone burden ( &lt; or = 50%) groups were 7.78% +/- 5.51% and 3.45% +/- 3.34%, 56.06 +/- 14.28 g/L and 76.40 +/- 24.44 g/L, (1.82 +/- 0.48) x 10(12)/L and (2.32 +/- 0.66) x 10(12)/L, respectively (<z:hpo ids='HP_0000001'>all</z:hpo> P &lt; 0.05) </plain></SENT>
<SENT sid="6" pm="."><plain>CD4+ T lymphocytes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> controls were (0.274 +/- 0.719) x 10(9)/L and (0.455 +/- 0.206) x 10(9)/L, respectively (P &lt; 0.05) </plain></SENT>
<SENT sid="7" pm="."><plain>CD8+ T lymphocytes of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> controls were (0.240 +/- 0.150) x 10(9)/L and (0.305 +/- 0.145) x 10(9)/L, respectively </plain></SENT>
<SENT sid="8" pm="."><plain>The serum level of interleukin-2 of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (6.29 +/- 3.58 ng/mL) was significantly higher than <z:mpath ids='MPATH_458'>normal</z:mpath> control (3.11 +/- 1.40 ng/mL, P &lt; 0.05) </plain></SENT>
<SENT sid="9" pm="."><plain>The serum level of TNF of <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients and <z:mpath ids='MPATH_458'>normal</z:mpath> control group were 2.42 +/- 1.79 ng/mL and 1.68 +/- 0.69 ng/mL, respectively </plain></SENT>
<SENT sid="10" pm="."><plain>The ratio of CD4 to CD8 was higher in high clone burden <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> patients (1.90 +/- 0.52) than that in low clone burden patients (0.97 +/- 0.44, P &lt; 0.05) </plain></SENT>
<SENT sid="11" pm="."><plain>CONCLUSION: The quantitive clonal karyotype abnormalities and deficient T cell immunity are important parameters for evaluating <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e> severity and predicting its progression </plain></SENT>
</text></document>